Just weeks ago Astellas teamed up with Harvard's Constance Cepko on a new program for a degenerative eye disease. Today it inked a deal with Proteostasis Therapeutics that could be worth up to $1.2 billion while getting Dana-Farber investigators to help hunt down new cancer drugs that can inhibit K-Ras.
The University of Manchester's North West Centre for Advanced Drug Delivery will study drug delivery topics in cancer and other diseases of interest to the AstraZeneca, in the latest example of the growing research collaboration between Big Pharma and academia.
More than three years after inking a $750 million pact to develop Intra-Cellular's PDE1 inhibitors for cognitive impairment caused by schizophrenia, Takeda is out.
Making medical device prototypes using 3-D injection molding, rather than traditional aluminum molds, could reduce the costs and time associated with the product creation and iteration process. That's what major 3-D printer Stratasys is betting on with its new partnership with Worrell.
GreatCall, maker of mobile health and safety apps, is adding the AliveCor Heart Monitor for detecting atrial fibrillation to its offerings. Alivecor's electrocardiogram can now be mounted to back of the GreatCall3 smartphone and used with the AliveECG app.
QuantuMDx is teaming up with a Swiss nonprofit organization to develop its handheld test for tuberculosis, building momentum for a full commercial rollout of its innovative diagnostic tool.
Plasma protein specialist CSL Behring has tied the knot with Ohio devicemaker Enable Injections to use Enable's technology for the delivery of treatments for chronic diseases. The development agreement will give CSL access to market the device.
Eye care company pSivida will use the $25 million milestone payment for the recent FDA approval of sustained-release therapy Iluvien to fund its pipeline.
Xencor has reacquired the rights to an Amgen-optioned antibody, walking away from the Big Biotech and an arthritis indication with hopes of a new path in rare disease.
J&J is officially cutting the ribbon on its new partnering office in Shanghai, completing the pharma giant's global plan to hit the ground running in all the world's top biotech hot spots. It's taking the wraps off of a lineup of new discovery deals with universities in the region. And it's spreading out feelers for more deals through satellite offices in Australia, Singapore and Japan.